Free Trial

Eliem Therapeutics (ELYM) 10K Form and Latest SEC Filings 2026

Eliem Therapeutics logo
$9.69 +0.78 (+8.75%)
As of 05/4/2026

Latest Eliem Therapeutics SEC Filings & Recent Activity

Eliem Therapeutics (NASDAQ:ELYM) has submitted 175+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on May 5, 2026.

Form 4
Climb Bio, Inc. Reports Ownership Change on Apr. 29, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Eliem Therapeutics Files Current Report on May. 5, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Eliem Therapeutics Files Annual Report on Mar. 5, 2026

The 10-K contains Eliem Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Eliem Therapeutics SEC Filing History

Browse Eliem Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/05/2026 6:45 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2026 5:44 PM
Eliem Therapeutics (1768446) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13D/A
04/29/2026 5:46 PM
Eliem Therapeutics (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/28/2026 7:30 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2026 3:13 PM
Eliem Therapeutics (1768446) Filer
Form DEF 14A
04/24/2026 3:15 PM
Eliem Therapeutics (1768446) Filer
Form DEFA14A
04/24/2026 3:17 PM
Eliem Therapeutics (1768446) Filer
Form ARS
04/10/2026 3:05 PM
Eliem Therapeutics (1768446) Filer
Form PRE 14A
04/03/2026 3:05 PM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 6:20 AM
Eliem Therapeutics (1768446) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/05/2026 6:30 AM
Eliem Therapeutics (1768446) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/05/2026 6:10 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 3:05 PM
ALTSCHULLER Susan (1817988) Reporting
Eliem Therapeutics (1768446) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:05 PM
Eliem Therapeutics (1768446) Issuer
Wilson Perrin Megan (2074091) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:05 PM
Brennan Aoife (1714563) Reporting
Eliem Therapeutics (1768446) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 6:07 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 3:55 PM
Eliem Therapeutics (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2025 3:12 PM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/15/2025 6:55 PM
Eliem Therapeutics (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 6:56 PM
Eliem Therapeutics (1768446) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13D/A
12/11/2025 7:16 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2025 6:21 AM
Eliem Therapeutics (1768446) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 6:15 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 6:11 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/16/2025 4:48 PM
AI ETI LLC (1871741) Filed by
Eliem Therapeutics (1768446) Subject
Form SCHEDULE 13D/A
10/07/2025 3:51 PM
AI ETI LLC (1871741) Filed by
Eliem Therapeutics (1768446) Subject
Form SCHEDULE 13D/A
10/01/2025 4:52 PM
ALTSCHULLER Susan (1817988) Reporting
Eliem Therapeutics (1768446) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 4:49 PM
ALTSCHULLER Susan (1817988) Reporting
Eliem Therapeutics (1768446) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/01/2025 4:23 PM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 6:48 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/18/2025 8:26 AM
Eliem Therapeutics (1768446) Subject
Pontifax Management 4 G.P. (2015) Filed by
Form SCHEDULE 13G
08/12/2025 6:10 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2025 6:15 AM
Eliem Therapeutics (1768446) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/01/2025 3:32 PM
Eliem Therapeutics (1768446) Issuer
Thomas Stephen Basil (2027962) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2025 3:15 PM
Eliem Therapeutics (1768446) Issuer
Wilson Perrin Megan (2074091) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/20/2025 3:15 PM
Eliem Therapeutics (1768446) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/20/2025 3:20 PM
Eliem Therapeutics (1768446) Issuer
Pimblett Emily (1969365) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2025 3:20 PM
Eliem Therapeutics (1768446) Issuer
Driscoll Cindy (1741269) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025 6:08 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2025 3:21 PM
Eliem Therapeutics (1768446) Issuer
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund II, L.P. (1825376) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
RA Capital Nexus Fund, L.P. (1780117) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/23/2025 3:32 PM
Eliem Therapeutics (1768446) Filer
Form DEFA14A
05/14/2025 6:05 AM
Eliem Therapeutics (1768446) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2025 6:10 AM
Eliem Therapeutics (1768446) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Eliem Therapeutics SEC Filings - Frequently Asked Questions

Eliem Therapeutics (ELYM) has submitted 175+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Eliem Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 8-K submitted on May 5, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ELYM) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners